News Briefing channel feed

EMA ini­ti­ates safe­ty re­view on JAK in­hibitors; Gala­pa­gos woes con­tin­ue as it ter­mi­nates lat­est study 

4 years ago

An­oth­er year, an­oth­er $9M in BAR­DA fund­ing for Medi­Wound; Af­ter PhI­II re­sults, Scynex­is will sub­mit NDA for oral yeast in­fec­tion drug

4 years ago

Bio­Marin lands $110m sale of pri­or­i­ty re­view vouch­er; Hy­bridize li­cens­es out BK virus ther­a­py

4 years ago

New AI start­up launch­es with $40M; Ob­sE­va an­nounces reg­u­la­to­ry holdup for flag­ship drug

4 years ago

Or­chard se­cures re­im­burse­ment for gene ther­a­py; UK fines drug­mak­ers $47M for an­ti­com­pet­i­tive scheme

4 years ago

Macro­Gen­ics ear­marks $580M for ADC tech; Do­mainex, non­prof­it team up on Parkin­son's pro­gram

4 years ago
R&D

4SC pulls plug on do­mati­no­s­tat; Pharm­ing says le­niolis­ib meets both end­points

4 years ago

Af­ter land­ing funds from Roy­al­ty, Cy­to­ki­net­ics an­nounces afi­camten PhII re­sults; Pol­ish CRO Selvi­ta re­struc­tures in search for new growth

4 years ago

Capri­cor gets up to $735M for Duchenne drug's US rights; PCI Biotech ends bile duct can­cer clin­i­cal tri­al

4 years ago

BeiGene/No­var­tis tout new PD-1 da­ta; No­var­tis plans down­siz­ing in Tokyo

4 years ago

Yingli Phar­ma brings small mol­e­cule re­search to the US in new pact with MD An­der­son; UCB's pso­ri­at­ic arthri­tis drug shows pos­i­tive PhI­II re­sults

4 years ago

Chi­nese biotech teams with Lil­ly on car­diometa­bol­ic dis­eases; Sen­ate fi­nance chair goes af­ter BMS

4 years ago

En­do reach­es opi­oid set­tle­ment in Flori­da; De­moc­rats call on CMS to low­er pre­mi­ums fol­low­ing Aduhelm price cut

4 years ago

Eye dis­ease biotech rais­es $46.9M in Se­ries B; Jour­ney Med­ical Cor­po­ra­tion shells out $20M up­front for der­ma­tol­ogy fran­chise

4 years ago

Can virus-like par­ti­cles un­leash a new wave of CRISPR treat­ments?; Fo­s­un Phar­ma and In­sil­i­co team up in AI dis­cov­ery deal

4 years ago

Se­lec­ta turns to syn­bio play­er for $1.1B cap­sid deal; BioN­Tech signs $790M im­munother­a­py deal

4 years ago

So­sei and Ver­i­ly part­ner on GPCRs; Ob­sE­va touts PhI­II da­ta in en­dometrio­sis pain

4 years ago

An­nex­on shares fall 33% af­ter pa­tients drop out of Hunt­ing­ton's tri­al; Two Chi­nese biotechs net mod­est fi­nanc­ing rounds

4 years ago

As­traZeneca hands off epilep­sy pro­grams to Ovid; Amy­lyx scores pri­or­i­ty re­view for ALS drug 

4 years ago

Durect out-li­cens­es anal­gesic Posimir to Irish biotech in $136M deal; Ar­cutis gets 9-fig­ure loan to push for OK for pso­ri­a­sis cream

4 years ago

Boston start­up lands $28M, clos­es small biotech buy­out; New longevi­ty fund takes shape

4 years ago

Am­gen's Ote­zla bags ex­pand­ed FDA nod in pso­ri­a­sis; I-Mab CEO hits the ex­it amid shake­up at Chi­nese firm

4 years ago

Ab­b­Vie pe­ti­tions trade com­mis­sion to ban Alvotech's Hu­mi­ra biosim­i­lar; Cy­to­ki­net­ics li­cens­es heart drug to Chi­nese part­ner

4 years ago

Pur­due's mul­ti-bil­lion dol­lar set­tle­ment in jeop­ardy af­ter fed­er­al judge toss­es deal; Bio­Marin an­nounces glob­al gene ther­a­py col­lab­o­ra­tion

4 years ago
First page Previous page 23242526272829 Next page Last page
A service from the Financial Times